Conference
Continued Fracture Risk Reduction After 12 Months of Romosozumab Followed by Denosumab Through 36 Months in the Phase 3 FRAME (FRActure study in postmenopausal woMen with ostEoporosis) Extension.
Authors
Lewiecki EM; Dinavahi RV; Lazaretti-Castro M; Ebeling PR; Adachi JD; Miyauchi A; Gielen E; Milmont CE; Libanati C; Grauer A
Volume
32
Pagination
pp. S24-S24
Publisher
WILEY
Publication Date
December 1, 2017
Name of conference
Annual Meeting of the American-Society-for-Bone-and-Mineral-Research (ASBMR)
Conference place
Denver, CO
Conference start date
September 8, 2017
Conference end date
September 11, 2017
Conference proceedings
JOURNAL OF BONE AND MINERAL RESEARCH
ISSN
0884-0431